ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 229 entries already.
After the exuberance during the Covid-boost and the post-Covid hangover, 2024 was a rather calm year for the biotechnology sector. This provides an opportunity to take a step back and assess some emerging long-term financing trends as well as the recent events in the US, which may also impact the biotech industry.
Cambridge-based 4basebio PLC announced the appointment of Gabe Longoria as Chief Commercial Officer.
During the conference calls on the latest quarterly reports, several recurring questions emerged: What consequences do you anticipate if Trump is to be re-elected? How will tariffs affect supply chains and operating profits? What about FDA, IRA, the healthcare system, or the bioeconomy strategy?
Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.
Dr Sonya Montgomery joined OSE Immunotherapeutics SA, based in Nantes, France, as Chief Development Officer.
Cambridge-based biotechnology company Nuclera has appointed William J. Kullback to its board of directors as a non-executive director.
Kufstein-based Single Use Support appointed Darren Verlenden as CEO and strengthens leadership team.
Matt Gunnison was appointed as the new CEO of Biosynth, headquartered in Staad (CH). He started in November.
The French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.
The study of G protein-coupled receptor (GPCR) signalling is crucial for understanding a wide range of physiological processes. Among the methods used to monitor calcium signalling, Aequorin stands out for its high sensitivity, specificity, and sub-cellular compartment targeting. While many CROs are still using fluorescent calcium dyes, EuroscreenFast is making use of Aequorin’s unique properties as an invaluable tool to delve into the complexities of cellular communication.